Global Gene Therapy On Cardiovascular Disease Competitive Landscape Professional Research Report 2025
Description
Global Gene Therapy On Cardiovascular Disease Competitive Landscape Professional Research Report 2025
Research Summary
Gene therapy for cardiovascular diseases involves the use of genetic interventions to address underlying issues contributing to heart-related disorders. This therapeutic approach aims to modify or introduce specific genes to improve the function of the cardiovascular system. In the context of cardiovascular diseases, gene therapy may target conditions such as ischemic heart disease, heart failure, or genetic disorders affecting cardiac function. Strategies include enhancing blood vessel formation, promoting cell survival, or modulating the expression of genes associated with cardiac health. Researchers are exploring gene therapy approaches to improve angiogenesis, reduce inflammation, and enhance myocardial function. While gene therapy for cardiovascular diseases is still in the experimental stage, early clinical trials and preclinical studies suggest the potential for novel treatment options to address the complex mechanisms involved in these conditions, offering hope for more effective and targeted interventions in the future.
According to DIResearch's in-depth investigation and research, the global Gene Therapy On Cardiovascular Disease market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.
The major global manufacturers of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Human Stem Cells Institute, Orchard Therapeutics etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Gene Therapy On Cardiovascular Disease. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Gene Therapy On Cardiovascular Disease market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Gene Therapy On Cardiovascular Disease market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Gene Therapy On Cardiovascular Disease industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Gene Therapy On Cardiovascular Disease Include:
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Human Stem Cells Institute
Orchard Therapeutics
Gene Therapy On Cardiovascular Disease Product Segment Include:
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease Product Application Include:
Neurological Diseases
Cancer
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Gene Therapy On Cardiovascular Disease Industry PESTEL Analysis
Chapter 3: Global Gene Therapy On Cardiovascular Disease Industry Porter’s Five Forces Analysis
Chapter 4: Global Gene Therapy On Cardiovascular Disease Major Regional Market Size and Forecast Analysis
Chapter 5: Global Gene Therapy On Cardiovascular Disease Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Passenger Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Gene Therapy On Cardiovascular Disease Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Gene Therapy On Cardiovascular Disease Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents
170 Pages
- 1 Gene Therapy On Cardiovascular Disease Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Gene Therapy On Cardiovascular Disease Product by Type
- 1.2.1 Viral Gene Therapy
- 1.2.2 Non-Viral Gene Therapy
- 1.3 Gene Therapy On Cardiovascular Disease Product by Application
- 1.3.1 Neurological Diseases
- 1.3.2 Cancer
- 1.3.3 Other
- 1.4 Global Gene Therapy On Cardiovascular Disease Market Size Analysis (2020-2032)
- 1.5 Gene Therapy On Cardiovascular Disease Market Development Status and Trends
- 1.5.1 Gene Therapy On Cardiovascular Disease Industry Development Status Analysis
- 1.5.2 Gene Therapy On Cardiovascular Disease Industry Development Trends Analysis
- 2 Gene Therapy On Cardiovascular Disease Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Gene Therapy On Cardiovascular Disease Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Gene Therapy On Cardiovascular Disease Market Analysis by Regions
- 4.1 Gene Therapy On Cardiovascular Disease Overall Market: 2024 VS 2025 VS 2032
- 4.2 Global Gene Therapy On Cardiovascular Disease Revenue and Forecast Analysis (2020-2032)
- 4.2.1 Global Gene Therapy On Cardiovascular Disease Revenue and Market Share by Region (2020-2025)
- 4.2.2 Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Region (2026-2032)
- 5 Global Gene Therapy On Cardiovascular Disease Market Size by Type and Application
- 5.1 Global Gene Therapy On Cardiovascular Disease Market Size by Type (2020-2032)
- 5.2 Global Gene Therapy On Cardiovascular Disease Market Size by Application (2020-2032)
- 6 North America
- 6.1 North America Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 6.2 North America Key Manufacturers Analysis
- 6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Type
- 6.4 North America Gene Therapy On Cardiovascular Disease Market Size by Application
- 6.5 North America Gene Therapy On Cardiovascular Disease Market Size by Country
- 6.5.1 US
- 6.5.2 Canada
- 7 Europe
- 7.1 Europe Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 7.2 Europe Key Manufacturers Analysis
- 7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Type
- 7.4 Europe Gene Therapy On Cardiovascular Disease Market Size by Application
- 7.5 Europe Gene Therapy On Cardiovascular Disease Market Size by Country
- 7.5.1 Germany
- 7.5.2 France
- 7.5.3 United Kingdom
- 7.5.4 Italy
- 7.5.5 Spain
- 7.5.6 Benelux
- 8 China
- 8.1 China Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 8.2 China Key Manufacturers Analysis
- 8.3 China Gene Therapy On Cardiovascular Disease Market Size by Type
- 8.4 China Gene Therapy On Cardiovascular Disease Market Size by Application
- 9 APAC (excl. China)
- 9.1 APAC (excl. China) Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 9.2 APAC (excl. China) Key Manufacturers Analysis
- 9.3 APAC (excl. China) Gene Therapy On Cardiovascular Disease Market Size by Type
- 9.4 APAC (excl. China) Gene Therapy On Cardiovascular Disease Market Size by Application
- 9.5 APAC (excl. China) Gene Therapy On Cardiovascular Disease Market Size by Country
- 9.5.1 Japan
- 9.5.2 South Korea
- 9.5.3 India
- 9.5.4 Australia
- 9.5.5 Southeast Asia
- 10 Latin America
- 10.1 Latin America Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 10.2 Latin America Key Manufacturers Analysis
- 10.3 Latin America Gene Therapy On Cardiovascular Disease Market Size by Type
- 10.4 Latin America Gene Therapy On Cardiovascular Disease Market Size by Application
- 10.5 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country
- 10.5.1 Mexico
- 10.5.2 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size and Growth Rate Analysis (2020-2032)
- 11.2 Middle East & Africa Key Manufacturers Analysis
- 11.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Type
- 11.4 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Application
- 11.5 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country
- 11.5.1 Saudi Arabia
- 11.5.2 South Africa
- 12 Competition by Manufacturers
- 12.1 Global Gene Therapy On Cardiovascular Disease Market Revenue by Key Manufacturers (2021-2025)
- 12.2 Gene Therapy On Cardiovascular Disease Competitive Landscape Analysis and Market Dynamic
- 12.2.1 Gene Therapy On Cardiovascular Disease Competitive Landscape Analysis
- 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales
- 12.2.3 Market Dynamic
- 13 Key Companies Analysis
- 13.1 Biogen
- 13.1.1 Biogen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.1.2 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.1.3 Biogen Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.2 Novartis
- 13.2.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.2.2 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.2.3 Novartis Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.3 Gilead Sciences
- 13.3.1 Gilead Sciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.3.2 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.4 Sarepta Therapeutics
- 13.4.1 Sarepta Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.4.2 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.5 Alnylam Pharmaceuticals
- 13.5.1 Alnylam Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.5.2 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.6 Amgen
- 13.6.1 Amgen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.6.2 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.6.3 Amgen Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.7 Spark Therapeutics
- 13.7.1 Spark Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.7.2 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.8 Akcea Therapeutics
- 13.8.1 Akcea Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.8.2 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.9 bluebird bio
- 13.9.1 bluebird bio Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.9.2 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.10 Sunway Biotech
- 13.10.1 Sunway Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.10.2 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.11 SIBIONO
- 13.11.1 SIBIONO Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.11.2 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.12 AnGes
- 13.12.1 AnGes Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.12.2 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.12.3 AnGes Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.13 Human Stem Cells Institute
- 13.13.1 Human Stem Cells Institute Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.13.2 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.13.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 13.14 Orchard Therapeutics
- 13.14.1 Orchard Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 13.14.2 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 13.14.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 14 Industry Chain Analysis
- 14.1 Gene Therapy On Cardiovascular Disease Industry Chain Analysis
- 14.2 Gene Therapy On Cardiovascular Disease Industry Raw Material and Suppliers Analysis
- 14.2.1 Gene Therapy On Cardiovascular Disease Key Raw Material Supply Analysis
- 14.2.2 Raw Material Suppliers and Contact Information
- 14.3 Gene Therapy On Cardiovascular Disease Typical Downstream Customers
- 14.4 Gene Therapy On Cardiovascular Disease Sales Channel Analysis
- 15 Research Findings and Conclusion
- 16 Methodology and Data Source
- 16.1 Methodology/Research Approach
- 16.2 Research Scope
- 16.3 Benchmarks and Assumptions
- 16.4 Date Source
- 16.4.1 Primary Sources
- 16.4.2 Secondary Sources
- 16.5 Data Cross Validation
- 16.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
